Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy

Sponsors

Lead Sponsor: Novartis Pharmaceuticals

Source Novartis
Brief Summary

To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.

Overall Status Completed
Start Date 2003-06-01
Primary Completion Date 2010-07-01
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment. 2 - 4 weeks
Secondary Outcome
Measure Time Frame
investigate the time to sustained biochemical response under the treatment of Glivec® in this patient population continuous
investigate duration of biochemical sustained response under the treatment with Glivec® in this patient population. continuous
To assess the response rates: number of patients with complete, partial and minor biochemical response and stable PSA continuous
To assess the time to clinical progression of this patient population treated with Glivec® at this dose and schedule. continuous
To descriptively characterize the safety and tolerability of Glivec® administered at this dose and schedule to this patient population. continuous
Enrollment 51
Condition
Intervention

Intervention Type: Drug

Intervention Name: STI571 (Glivec®)

Arm Group Label: imatinib mesylate

Other Name: Glivec

Eligibility

Criteria:

Inclusion Criteria: - who are 18 years of age or older. - who have undergone radical prostatectomy within 2 years prior to PSA progression . - exhibiting two consecutive rises in PSA levels relative to a previous reference value, separated by 14 days. The first measurement must occur 14 days after the reference value und must be at least 20% above the reference value. The reference value must be at least 0.4 ng/ml. The second confirmatory measurement taken 14 days after the first measurement must be greater than the first measurement. - with a Karnofsky Performance Score (KPS) greater than or equal to 90 (Appendix 5). - with the following hematologic lab values: ANC greater than or equal to 1500/mm3, Hgb greater than or equal to 10g/dL, PLT greater than or equal to 100x109/L. - with the following biochemistry lab values: total bilirubin < 1.5 ULN, SGOT, SGPT less than or equal to 2.5 ULN, serum creatinine less than or equal to 1.5 ULN. - willing to employ an effective barrier method of contraception during the study duration and for 3 months following discontinuation of study drug (for patients of reproductive potential). - with a life expectancy of > 6 months. - who have provided written informed consent pursuant to local regulatory requirements prior to initiation of any study procedure. with a Gleason Score > 6 in the prostatectomy specimen Exclusion Criteria: - with a history of another malignancy within 5 years prior to study entry, except curatively treated non-melanotic skin cancer, unless written approval is obtained by the sponsor. - with prior hormonal therapy - who require therapy with warfarin or analgesics of the morphine class or higher (see Section 3.4.4). - with a known diagnosis of HIV, hepatitis B, or hepatitis C infection. - who have had a major surgery within 2 weeks prior to study entry. - with severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency (NYHA III or IV, see Appendix 2), uncontrolled diabetes, chronic hepatic or renal disease, and active uncontrolled infection. - with a history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits. Other protocol-defined inclusion/exclusion criteria may apply

Gender:

Male

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Novartis Pharmaceuticals Study Director Novartis Pharmaceuticals
Location
Facility:
Novartis Investigative Site | Aachen, Germany
Novarts Investigative Site | Berlin, Germany
Novartis Investigative Site | Bonn, Germany
Novartis Investigative Site | Borken, Germany
Novartis Investigative Site | Darmstadt, Germany
Novartis Investigative Site | Fürth, Germany
Novartis Investigative Site | Gardelegen, Germany
Novarts Investigative Site | Hamburg, Germany
Novartis Investigative Site | Köln, Germany
Novartis Investigative Site | Marburg, Germany
Novartis Investigative Site | Ulm, Germany
Novartis Investigative Site | Wesel, Germany
Novartis Investigative Site | Wuppertal, Germany
Location Countries

Germany

Verification Date

2011-03-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: imatinib mesylate

Type: Experimental

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News